Glanzmann thrombasthenia anti-αIIbβ3 isoantibodies coagulation complement activation platelet transfusion procoagulant platelet

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 24 05 2023
revised: 13 09 2023
accepted: 11 10 2023
medline: 25 1 2024
pubmed: 25 1 2024
entrez: 25 1 2024
Statut: epublish

Résumé

Glanzmann thrombasthenia (GT) is a rare bleeding disorder caused by inherited defects of the platelet α In this study, we aimed to determine the prevalence of such isoantibodies and better characterize their pathogenic properties. Twelve patients with GT were evaluated for anti-α Only 2 samples were able to severely block integrin function. We observed that these 2 sera caused a reduction in platelet size similar to that observed when platelets become procoagulant. Mixing healthy donor platelets with patients' sera or purified IgGs led to microvesiculation, phosphatidylserine exposure, and induction of calcium influx. This was associated with an increase in procoagulant platelets. Pore formation and calcium entry were associated with complement activation, leading to the constitution of a membrane attack complex (MAC) with enhanced complement protein C5b-9 formation. This process was inhibited by the complement 5 inhibitor eculizumab and reduced by polyvalent human immunoglobulins. Our data suggest that complement activation induced by rare blocking anti-α

Sections du résumé

Background UNASSIGNED
Glanzmann thrombasthenia (GT) is a rare bleeding disorder caused by inherited defects of the platelet α
Objectives UNASSIGNED
In this study, we aimed to determine the prevalence of such isoantibodies and better characterize their pathogenic properties.
Methods UNASSIGNED
Twelve patients with GT were evaluated for anti-α
Results UNASSIGNED
Only 2 samples were able to severely block integrin function. We observed that these 2 sera caused a reduction in platelet size similar to that observed when platelets become procoagulant. Mixing healthy donor platelets with patients' sera or purified IgGs led to microvesiculation, phosphatidylserine exposure, and induction of calcium influx. This was associated with an increase in procoagulant platelets. Pore formation and calcium entry were associated with complement activation, leading to the constitution of a membrane attack complex (MAC) with enhanced complement protein C5b-9 formation. This process was inhibited by the complement 5 inhibitor eculizumab and reduced by polyvalent human immunoglobulins.
Conclusion UNASSIGNED
Our data suggest that complement activation induced by rare blocking anti-α

Identifiants

pubmed: 38268518
doi: 10.1016/j.rpth.2023.102253
pii: S2475-0379(23)05678-9
pmc: PMC10805943
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102253

Informations de copyright

© 2023 The Authors.

Auteurs

Christine S M Lee (CSM)

ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.

Yoann Huguenin (Y)

Competence Centre for Inherited Bleeding Disorders, University Hospital of Bordeaux, Bordeaux, France.

Xavier Pillois (X)

French Reference Centre for Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France.

Mikeldi Moulieras (M)

French Reference Centre for Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France.

Ella Marcy (E)

French Reference Centre for Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France.

Shane Whittaker (S)

ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.

Vivien M Y Chen (VMY)

ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Department of Haematology, Concord Repatriation General Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.

Mathieu Fiore (M)

French Reference Centre for Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France.
Department of Haematology, University Hospital of Bordeaux, Pessac, France.
Inserm U1034, Biology of Cardiovascular Disease, Pessac, France.

Classifications MeSH